Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia

被引：31
|
作者：
Coombs, Catherine C. [1 ]
Sallman, David A. [2 ]
Devlin, Sean M. [3 ]
Dixit, Shweta
Mohanty, Abhinita [5 ]
Knapp, Kristina [4 ]
Al Ali, Najla H. [2 ]
Lancet, Jeffrey E. [2 ]
List, Alan F. [2 ]
Komrokji, Rami S. [2 ]
Padron, Eric [2 ]
Arcila, Maria E. [5 ]
Klimek, Virginia M. [1 ]
van den Brink, Marcel R. M. [6 ]
Tallman, Martin S. [1 ,7 ]
Levine, Ross L. [1 ,4 ]
Rampal, Raajit K. [1 ]
Rapaport, Franck [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[3] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
[6] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA
[7] Weill Cornell Med Coll, New York, NY USA
来源：
HAEMATOLOGICA | 2016年 / 101卷 / 11期
关键词：
OLDER PATIENTS; AZACITIDINE; PHENOTYPE; DNMT3A; IMPACT; IDH2; CARE; AML;
D O I：
10.3324/haematol.2016.148999
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E457 / E460
页数：4
相关论文
共 50 条
  • [41] Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam M.
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Benton, Christopher B.
    Benton, Christopher B.
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa E.
    Jain, Nitin
    Kornblau, Steven M.
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias
    Masarova, Lucia
    Rytting, Michael E.
    Thompson, Philip A.
    Wang, Sa A.
    Konoplev, Sergej
    Chen, Zhining
    Goswami, Maitrayee
    Maduike, Rita
    Guerrero, Julio A.
    Zhang, Qi
    Cavazos, Antonio
    Ma, Helen
    Bivins, Carol A.
    Wade, Allison
    Adewale, Shadiat L.
    Tse, Susan
    Thomas, Robin
    Vaughan, Kenneth
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD, 2019, 134
  • [42] Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
    Ball, Brian
    Komrokji, Rami S.
    Ades, Lionel
    Sekeres, Mikkael A.
    DeZern, Amy E.
    Pleyer, Lisa
    Vey, Norbert
    Almeida, Antonio
    Germing, Ulrich
    Cluzeau, Thomas
    Platzbecker, Uwe
    Gore, Steven D.
    Fenaux, Pierre
    Prebet, Thomas
    BLOOD ADVANCES, 2018, 2 (16) : 2063 - 2071
  • [43] Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy
    Sang-Bo Oh
    Sung-Woo Park
    Joo-Seop Chung
    Won-Sik Lee
    Ho-Seop Lee
    Su-Hee Cho
    Yoon-Suk Choi
    Sung-Nam Lim
    Ho-Jin Shin
    Annals of Hematology, 2017, 96 : 1801 - 1809
  • [44] Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy
    Oh, Sang-Bo
    Park, Sung-Woo
    Chung, Joo-Seop
    Lee, Won-Sik
    Lee, Ho-Seop
    Cho, Su-Hee
    Choi, Yoon-Suk
    Lim, Sung-Nam
    Shin, Ho-Jin
    ANNALS OF HEMATOLOGY, 2017, 96 (11) : 1801 - 1809
  • [45] ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival
    McCullough, Kristen
    Karrar, Omer
    Iftikhar, Moazah
    Abdelmagid, Maymona
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Saliba, Antoine
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Patnaik, Mrinal M.
    Pardanani, Animesh D.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2023, 142
  • [46] Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study
    Gabellier, Ludovic
    Peterlin, Pierre
    Thepot, Sylvain
    Hicheri, Yosr
    Paul, Franciane
    Gallego-Hernanz, Maria Pilar
    Bertoli, Sarah
    Turlure, Pascal
    Pigneux, Arnaud
    Guieze, Romain
    Ochmann, Marlene
    Malfuson, Jean-Valere
    Cluzeau, Thomas
    Thomas, Xavier
    Tavernier, Emmanuelle
    Jourdan, Eric
    Bonnet, Sarah
    Tudesq, Jean-Jacques
    Raffoux, Emmanuel
    ANNALS OF HEMATOLOGY, 2024, 103 (03) : 759 - 769
  • [47] Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease
    Sanber, Khaled
    Ye, Kevin
    Tsai, Hua-Ling
    Newman, Matthew
    Webster, Jonathan A.
    Gojo, Ivana
    Ghiaur, Gabriel
    Prince, Gabrielle T.
    Gondek, Lukasz P.
    Smith, B. Douglas
    Levis, Mark J.
    DeZern, Amy E.
    Ambinder, Alexander J.
    Dalton, William B.
    Jain, Tania
    LEUKEMIA & LYMPHOMA, 2023, 64 (04) : 846 - 855
  • [48] Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.
    Takahashi, Koichi
    Kantarjian, Hagop M.
    Ghanem, Hady
    Ravandi, Farhad
    Cortes, Jorge E.
    Kadia, Tapan M.
    O'Brien, Susan
    Pierce, Sherry A.
    Jain, Nitin
    Garcia-Manero, Guillermo
    Jabbour, Elias J.
    BLOOD, 2012, 120 (21)
  • [49] Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia
    Delmas, Audrey
    Batchelder, Laurie
    Arora, Ira
    Bayet, Solene
    Bruhn, David
    Eberhardt, Alice
    Philpott, Stephanie
    Rodriguez-Leboeuf, Ana Maria
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study
    Ludovic Gabellier
    Pierre Peterlin
    Sylvain Thepot
    Yosr Hicheri
    Franciane Paul
    Maria Pilar Gallego-Hernanz
    Sarah Bertoli
    Pascal Turlure
    Arnaud Pigneux
    Romain Guieze
    Marlène Ochmann
    Jean-Valère Malfuson
    Thomas Cluzeau
    Xavier Thomas
    Emmanuelle Tavernier
    Eric Jourdan
    Sarah Bonnet
    Jean-Jacques Tudesq
    Emmanuel Raffoux
    Annals of Hematology, 2024, 103 : 759 - 769
12345